Mostrar el registro sencillo del ítem
dc.contributor.author | Muñoz García, Patricia | |
dc.contributor.author | Villa, Sofía de la | |
dc.contributor.author | Martínez Sellés Oliveria Soares, Manuel | |
dc.contributor.author | Goenaga, Miguel Ángel | |
dc.contributor.author | Reviejo Jaka, Karlos | |
dc.contributor.author | Arnáiz de las Revillas, Francisco | |
dc.contributor.author | García Cuello, Luis | |
dc.contributor.author | Hidalgo Tenorio, Carmen | |
dc.contributor.author | Rodríguez Esteban, María Ascensión | |
dc.contributor.author | Bouza, Emilio | |
dc.contributor.author | Spanish Collaboration on Endocarditis, Grupo de Apoyo al Manejo de la Endocarditis Infecciosa en España (GAMES) | |
dc.contributor.author | Et al. | |
dc.date.accessioned | 2022-07-27T18:16:48Z | |
dc.date.available | 2022-07-27T18:16:48Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Muñoz, P., Villa, S., Martínez-Sellés, M., Goenaga, M. A., Reviejo-Jaka, K., Revillas, F., García-Cuello, L., Hidalgo-Tenorio, C., Rodríguez-Esteban, M. A., Antorrena, I., Castelo-Corral, L., García-Vázquez, E., Torre, J., Bouza, E., & Spanish Collaboration on Endocarditis- Grupo de Apoyo al Manejo de la Endocarditis Infecciosa en España (GAMES). (2021). Linezolid for infective endocarditis: A structured approach based on a national database experience. Medicine, 100(51), e27597. https://doi.org/10.1097/MD.0000000000027597 | spa |
dc.identifier.issn | 0025-7974 | |
dc.identifier.issn | 1536-5964 | |
dc.identifier.uri | http://hdl.handle.net/11268/11539 | |
dc.description.abstract | Current data on the frequency and efficacy of linezolid (LNZ) in infective endocarditis (IE) are based on small retrospective series. We used a national database to evaluate the effectiveness of LNZ in IE.This is a retrospective study of IE patients in the Spanish GAMES database who received LNZ. We defined 3 levels of therapeutic impact: LNZ < 7 days, LNZ high-impact (≥ 7 days, > 50% of the total treatment, and > 50% of the LNZ doses prescribed in the first weeks of treatment), and LNZ ≥ 7 days not fulfilling the high-impact criteria (LNZ-NHI). Effectiveness of LNZ was assessed using propensity score matching and multivariate analysis of high-impact cases in comparison to patients not treated with LNZ from the GAMES database matched for age-adjusted comorbidity Charlson index, heart failure, renal failure, prosthetic and intracardiac IE device, left-sided IE, and Staphylococcus aureus. Primary outcomes were in-hospital mortality and one-year mortality. Secondary outcomes included IE complications and relapses.From 3467 patients included in the GAMES database, 295 (8.5%) received LNZ. After excluding 3 patients, 292 were grouped as follows for the analyses: 99 (33.9%) patients in LNZ < 7 days, 11 (3.7%) in LNZ high-impact, and 178 (61%) in LNZ-NHI. In-hospital mortality was 51.5%, 54.4%, and 19.1% respectively. In the propensity analysis, LNZ high-impact group presented with respect to matched controls not treated with LNZ higher in-hospital mortality (54.5% vs 18.2%, P = .04). The multivariate analysis showed an independent relationship of LNZ use with in-hospital mortality (odds ratio 9.06, 95% confidence interval 1.15--71.08, P = .03).Treatment with LNZ is relatively frequent, but most cases do not fulfill our high-impact criteria. Our data suggest that the use of LNZ as definitive treatment in IE may be associated with higher in-hospital mortality. | spa |
dc.description.sponsorship | Sin financiación | spa |
dc.language.iso | eng | spa |
dc.rights | Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) | spa |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0/ | spa |
dc.subject.other | Endocarditis bacteriana | spa |
dc.subject.other | Linezolid | spa |
dc.subject.other | Signos y síntomas | spa |
dc.title | Linezolid for infective endocarditis: A structured approach based on a national database experience | spa |
dc.type | article | spa |
dc.description.impact | 1.817 JCR (2021) Q3, 123/172 Medicine, General & Internal | spa |
dc.description.impact | 0.470 SJR (2021) Q3, 1333/2489 Medicine (miscellaneous) | spa |
dc.description.impact | No data IDR 2021 | spa |
dc.identifier.doi | 10.1097/MD.0000000000027597 | |
dc.rights.accessRights | openAccess | spa |
dc.subject.unesco | Enfermedad cardiovascular | spa |
dc.subject.unesco | Tratamiento médico | spa |
dc.description.filiation | UEM | spa |
dc.relation.publisherversion | https://doi.org/10.1097/MD.0000000000027597 | spa |
dc.peerreviewed | Si | spa |